The GlaxoSmithKline asthma biologic mepolizumab (Nucala) improved quality of life in asthma patients, reports MedPage Today.
Mepolizumab has been shown to reduce exacerbation rates and dependency on oral corticosteroid use in patients with severe eosinophilic asthma, but its impact on health-related quality of life (HRQOL) has not been extensively studied.
Quality of life, as measured by the St. George’s Respiratory Questionnaire (SGRQ) at treatment-week 24, was the primary outcome in the GSK-sponsored multicenter, 19-country, phase 3b randomized trial, reported by Geoffrey L. Chubb, MD, of Yale School of Medicine, and colleagues, in The Lancet Respiratory Medicine.
Read the whole story at www.medpagetoday.com
